专利检索_ .产生3'磷酸单酯的核糖核酸内切酶专利检索_ .产生3'磷酸单酯的核糖核酸内切酶专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
141	NOVEL POWDERED MILK PRODUCT AND METHOD FOR PRODUCING THE SAME	US14418257	2012-07-31	US20150224178A1	2015-08-13	Aiko Ohmachi; Hiroaki Matsuyama; Yoshikazu Morita; Yuko Ishida; Takayuki Nara; Ken Kato; Atsushi Serizawa; Hiroshi Ueno; Hiroshi Urazono
The invention relates to a powdered milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 1.4 to 24 mg/15 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.35 to 10.
142	METHODS OF TREATING CANCER USING ANGIOGENIN OR AN ANGIOGENIN AGONIST	US14399852	2013-05-10	US20150104438A1	2015-04-16	Peter Hobman; Andrew Brown
The invention provides a method for treating cancer in a subject or a method of inducing an anti-tumour effect including reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing tumour invasiveness, reducing tumour weight, reducing tumour neovascularisation, improving time to disease progression (TDP) and/or improving survival, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist.
143	Pollen preferred promoters and methods of use	US13445288	2012-04-12	US09006515B2	2015-04-14	Andrew Mark Cigan; Shai J Lawit
Compositions and methods for regulating expression of heterologous nucleotide sequences in a plant are provided. Compositions include nucleotide sequences encompasses a strong pollen preferred promoter which drives strong, specific expression of gene products in pollen. Also provided is a method for expressing a heterologous nucleotide sequence in a plant using a promoter sequence disclosed herein.
144	ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF	US14533264	2014-11-05	US20150056253A1	2015-02-26	Stephane Bancel; Jason P. Schrum; Alexander Aristarkhov
Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent microbial infection, or to improve a subject's heath or wellbeing.
145	METHOD FOR PREPARING IMMOBILIZED ANGIOGENIN	US14470608	2014-08-27	US20150010979A1	2015-01-08	A. Satyanarayan Naidu
Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by covalent immobilization on a naturally occurring substrate, such as a polysaccharide substrate, are disclosed. In particular, the polysaccharide substrate includes galactose-rich polysaccharide.
146	Antimicrobial Activity Enhancing Agent	US14001570	2011-07-29	US20140134704A1	2014-05-15	Mai Murata; Hiroyuki Wakabayashi; Koji Yamauchi
An antimicrobial activity enhancing agent for lactoferrin or a lactoferrin hydrolysate, which contains ribonuclease-4 as an active ingredient, and a method for producing an antimicrobial activity enhancing agent for lactoferrin or a lactoferrin hydrolysate, which comprises (a) the step of contacting raw milk with a cation exchange resin to adsorb proteins in the raw milk to the cation exchange resin, (b) the step of washing the cation exchange resin having undergone the adsorption treatment, and flowing an elution solvent to elute a protein fraction having an isoelectric point of 8.0 to 10.0, and (c) the step of subjecting the eluted protein fraction to gel filtration using a gel filtration carrier to collect a fraction of a molecular weight of 30 kDa or less.
147	Multimeric Complexes with Improved in Vivo Stability, Pharmacokinetics and Efficacy	US13901737	2013-05-24	US20130323204A1	2013-12-05	Edmund A. Rossi; Chien-Hsing Chang; David M. Goldenberg
The present invention concerns multimeric complexes based on antibody fusion proteins comprising an AD moiety attached to the C-terminal end of each antibody light chain. The complexes further comprise effector moities attached to DDD moieties. Two copies of the DDD moiety form a dimer that binds to the AD moiety. The complexes may be trimers, pentamers, hexamers or other multimers. The effector moieties may be selected from a second antibody or antigen-binding fragment thereof, a cytokine, an interferon, a toxin, an antigen, a xenoantigen, a hapten, a protamine, a hormone, an enzyme, a ligand-binding protein, a pro-apoptotic agent and an anti-angiogenic agent. Surprisingly, attachment of the AD moiety to the C-terminal end of the antibody light chain results in improved pharmacokinetics and in vivo stability and efficacy, compared to homologous complexes wherein the AD moiety is attached to the antibody heavy chain.
148	USE OF ANGIOGENIN OR ANGIOGENIN AGONISTS FOR TREATING DISEASES AND DISORDERS	US12992501	2009-05-14	US20110151016A1	2011-06-23	Matthew McDonagh; Benjamin Cocks; Angus Tester; Peter Hobman
The invention provides a method of treating a disorder characterised by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuro-protection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.
149	Methods and Compositions for Modulating Immune Tolerance	US11992880	2006-09-28	US20110081370A1	2011-04-07	Arya Biragyn; Kouji Matsushima; Dolgor Bataar
The instant invention provides methods and compositions for modulation of the immune system. Specifically, the invention provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.
150	란피르나제 및/또는 암피나제를 사용하는 바이러스성 결막염의 치료	KR20187011450	2016-09-25	KR20180058791A	2018-06-01
본명세서는란피르나제및 암피나제, 란피르나제및/또는암피나제를포함하는조성물, 및란피르나제, 암피나제또는란피르나제및/또는암피나제를포함하는조성물을사용하여바이러스성결막염, 유행성각결막염, 및/또는인두결막열을치료하고, 바이러스의수준또는바이러스역가를감소또는억제시키고, 바이러스복제를감소또는억제시키고, 단백질합성을감소또는억제시키고, tRNA의수준을감소또는억제시키고, 염증유도분자및/또는염증유도프로스타글란딘의수준을감소또는억제시키고, 페록시솜증식체-활성화된수용체 (PPAR) 경로신호를자극또는향상시키고, M1 내지 M2의분해표현형변화를촉진시키고, Th1 및 Th2 사이토카인을조절하고/하거나, NFκB 경로신호를감소또는억제시키기위한방법및 용도를개시한다.
151	신규 단백질 소재	KR1020157004149	2012-07-31	KR1020150036688A	2015-04-07	오마치아이코; 마츠야마히로아키; 모리타요시카즈; 이시다유코; 나라다카유키; 가토겐; 세리자와아츠시
본발명은, 안전하고, 일상적으로섭취함으로써, 골다공증이나골절, 류머티즘, 관절염등의여러가지골질환의예방이나치료에유용한신규단백질소재를제공하는것을과제로한다. 또한, 본발명은, 경구섭취에의해골다공증이나골절, 류머티즘, 관절염등의여러가지골질환의예방이나치료에유용한골강화용음식품또는사료를제공하는것을과제로한다. 안지오제닌및/또는안지오제닌분해물을 2∼15 ㎎/100 ㎎함유하고, 또한, 시스타틴및/또는시스타틴분해물을, 안지오제닌및/또는안지오제닌분해물에대하여, 질량비 0.003∼0.6의범위로함유하는단백질소재. 이러한단백질소재를섭취함으로써, 뼈를강화, 특히골다공증이나골절, 류머티즘, 관절염등의여러가지골질환을예방및 치료할수 있다.
152	치즈류 및 그 제조 방법	KR1020157004148	2012-07-31	KR1020150036687A	2015-04-07	오마치아이코; 마츠야마히로아키; 모리타요시카즈; 이시다유코; 나라다카유키; 가토겐; 세리자와아츠시; 우에노히로시; 우라조노히로시
본발명은, 안전하고, 일상적으로섭취함으로써, 골다공증이나골절, 류머티즘, 관절염등의여러가지골질환의예방이나치료에유용한신규치즈류를제공하는것을과제로한다. 이는안지오제닌및/또는안지오제닌분해물을 6.5 mg/100 g∼160 ㎎/100 g 함유하고, 또한, 시스타틴및/또는시스타틴분해물을, 안지오제닌및/또는안지오제닌분해물에대하여, 질량비 0.02∼1.6의범위로함유하는치즈류에의해달성된다. 이러한치즈류를섭취함으로써, 뼈를강화할수 있고, 특히골다공증이나골절, 류머티즘, 관절염등의여러가지골질환의예방및 치료에도움이될 수있다.
153	신규 단백질 소재	KR1020157004087	2012-07-31	KR1020150036667A	2015-04-07	오마치아이코; 마츠야마히로아키; 모리타요시카즈; 이시다유코; 나라다카유키; 가토켄; 세리자와아츠시
본발명은, 안전하고, 일상적으로섭취함으로써, 골다공증이나골절, 류머티즘, 관절염등의여러가지골질환의예방이나치료에유용한신규단백질소재를제공하는것을과제로한다. 또한, 본발명은, 경구섭취에의해골다공증이나골절, 류머티즘, 관절염등의여러가지골질환의예방이나치료에유용한골강화용음식품또는사료를제공하는것을과제로한다. 상기과제는안지오제닌및/또는안지오제닌분해물을 2∼15 ㎎/100 ㎎함유하고, 또한, 락토페록시다아제및/또는락토페록시다아제분해물을, 안지오제닌및/또는안지오제닌분해물에대하여, 질량비 0.3∼20의범위에서함유하는단백질소재에의해해결된다. 이러한단백질소재를섭취함으로써, 뼈를강화, 특히골다공증이나골절, 류머티즘, 관절염등의여러가지골질환을예방및 치료할수 있다.
154	ANGIOGENIN FOR USE IN TREATING SKELETAL MUSCLE DISORDERS	EP09745302.1	2009-05-14	EP2303311B1	2018-08-01	MCDONAGH, Matthew; COCKS, Benjamin; TESTER, Angus; HOBMAN, Peter
The invention provides a method of treating a disorder characterized by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.
155	PHARMACEUTICALS FOR TREATMENT OF VIRAL INFECTIONS OF THE EYE	EP16731753.6	2016-06-13	EP3307238A1	2018-04-18	SQUIQUERA, Luis; SULLEY, Jamie
Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, the '805 variant, rAmphinase 2, and Amphinase 2, and the vehicle is an aqueous solution.
156	MULTIMERIC COMPLEXES WITH IMPROVED IN VIVO STABILITY, PHARMACOKINETICS AND EFFICACY	EP13797550.4	2013-05-24	EP2854845B1	2018-03-28	ROSSI, Edmund A.; CHANG, Chien-Hsing; GOLDENBERG, David M.
The present invention concerns multimeric complexes based on antibody fusion proteins comprising an AD moiety attached to the C-terminal end of each antibody light chain. The complexes further comprise effector moities attached to DDD moieties. Two copies of the DDD moiety form a dimer that binds to the AD moiety. The complexes may be trimers, pentamers, hexamers or other multimers. The effector moieties may be selected from a second antibody or antigen-binding fragment thereof, a cytokine, an interferon, a toxin, an antigen, a xenoantigen, a hapten, a protamine, a hormone, an enzyme, a ligand-binding protein, a pro-apoptotic agent and an anti-angiogenic agent. Surprisingly, attachment of the AD moiety to the C-terminal end of the antibody light chain results in improved pharmacokinetics and in vivo stability and efficacy, compared to homologous complexes wherein the AD moiety is attached to the antibody heavy chain.
157	BEVERAGE, AND METHOD FOR PRODUCING SAME	EP12882432.3	2012-07-31	EP2880998B1	2018-01-03	OHMACHI, Aiko; MATSUYAMA, Hiroaki; MORITA, Yoshikazu; ISHIDA, Yuko; NARA, Takayuki; KATO, Ken; SERIZAWA, Atsushi; UENO, Hiroshi; URAZONO, Hiroshi
The invention relates to a drink includes angiogenin and/or angiogenin hydrolysate in an amount of more than 0.8 mg/100 ml and not more than 150 mg/100 ml, and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.006 to 1.7.
158	FERMENTED MILK PRODUCT, AND METHOD FOR PRODUCING SAME	EP12882143.6	2012-07-31	EP2880982B1	2018-01-03	OHMACHI, Aiko; MATSUYAMA, Hiroaki; MORITA, Yoshikazu; ISHIDA, Yuko; NARA, Takayuki; KATO, Ken; SERIZAWA, Atsushi; UENO, Hiroshi; URAZONO, Hiroshi
The invention relates to provide a fermented milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 0.9 mg/100 g to 150 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23.
159	POWDERED MILK PRODUCT, AND METHOD FOR PRODUCING SAME	EP12882312.7	2012-07-31	EP2880983B1	2017-07-26	OHMACHI, Aiko; MATSUYAMA, Hiroaki; MORITA, Yoshikazu; ISHIDA, Yuko; NARA, Takayuki; KATO, Ken; SERIZAWA, Atsushi; UENO, Hiroshi; URAZONO, Hiroshi
The invention relates to a powdered milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 1.4 to 24 mg/15 g, and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.03 to 1.3.
160	BEVERAGE, AND METHOD FOR PRODUCING SAME	EP12882174	2012-07-31	EP2880997A4	2016-01-27	OHMACHI AIKO; MATSUYAMA HIROAKI; MORITA YOSHIKAZU; ISHIDA YUKO; NARA TAKAYUKI; KATO KEN; SERIZAWA ATSUSHI; UENO HIROSHI; URAZONO HIROSHI
The invention relates to a drink includes angiogenin and/or angiogenin hydrolysate in an amount of more than 0.8 mg/100 ml and not more than 150 mg/100 ml, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23.

2 3 4 5 6 7 8 9 10 11

该功能需要专业版企业版VIP权限，您可以：